ICAAC

Switch to desktop

Home

C2. Antibacterials: Surveys and/or Molecular Epidemiology of Resistance and Resistance Genes, Strains or Serotypes (Bacterial, not Viral or Fungal Resistance)


Meet-the-Experts

 

Top 10 ß-Lactamase Papers in 2012

Upon completion of this Meet-the-Experts Session, the participant should be able to:

  • Discuss the changing epidemiology of beta-lactamase mediated resistance;
  • Recite the novel beta-lactamases that are described; and
  • Identify the new mechanistic developments in the fields of beta-lactamase enzymology and inhibitors. 

Experts:
Robert A. Bonomo, MD; Louis Stokes Cleveland Dep. of VA Med. Ctr., Cleveland, OH.
Karen Bush, PhD; Indiana Univ., Bloomington, IN.

 

Anaerobes and Surveillance: Neglected or Not?

This session will provide an overview on anaerobic bacteria and their importance in surveillance studies. It will specifically address which species and which antibiotics should be included in surveillance studies. The session will also describe the appropriate susceptibility methods available for anaerobes.

Upon completion of this Meet-the-Experts Session, the participant should be able to:

  • Describe which mechanisms, species and antibiotics are the most appropriate to include for anaerobe surveillance studies; and
  • Recognize when and the most appropriate method(s) that should be used to perform antimicrobial susceptibility testing on anaerobes. 

Experts:
Ellie J. C. Goldstein, MD; UCLA David Geffen Sch. of Med., Santa Monica, CA.
David W. Hecht, MD, MS; Loyola Univ. Med. Ctr., Chicago, IL.

 

Clostridium difficile: The Management of Severe and Recurrent Infections

This session will provide an update on the management of severe and recurrent infections due to Clostridium difficile. It will specifically address the changing epidemiology of Clostridium difficile associated disease and the treatment options available for recurrent Clostridium difficile infection.

Upon completion of this Meet-the-Experts Session, the participant should be able to:

  • Describe which treatment options are available for recurrent Clostridium difficile infection; and
  • Recognize the changing epidemiology of Clostridium difficile associated disease. 

Experts:
Dale N. Gerding, MD; Loyola Univ. Chicago Stritch Sch. of Med., Chicago, IL.
Thomas Louie, MD; Univ. of Calgary, Calgary, Canada.

 

Detecting, Controlling, and Treating Carbapenemase-Producing Enterobacteriaceae

This session will provide an update on the detection, controlling, and treating of carbapenemase-producing Enterobacteriaceae. It will specifically address the changing epidemiology of carbapenemase-producing Enterobacteriaceae and the treatment options available for infections due to these multiple-drug resistant bacteria.

Upon completion of this Meet-the-Experts Session, the participant should be able to:

  • Describe which treatment options and control methods that are available for infections due to carbapenemase-producing Enterobacteriaceae; and
  • Recognize the changing epidemiology of carbapenemase-producing Enterobacteriaceae. 

Experts:
Rafael Canton, PhD; Hosp. Univ. Ramón y Cajal. Inst. Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
David Landman, MD; SUNY Downstate Med. Ctr., Brooklyn, NY.

 

Surveillance of Antimicrobial Resistance: Potential Sources of Bias

This session will provide an overview on the potential sources of bias in the surveillance of antimicrobial resistance. It will specifically address prevalence versus rate data and which methods can be used to overcome bias in the surveillance for antimicrobial resistance.

Upon completion of this Meet-the-Experts Session, the participant should be able to:

  • Describe which methods can be used to overcome bias in surveillance for antimicrobial resistance; and
  • Recognize prevalence and rate data for the epidemiological interpretation of antimicrobial resistance studies. 

Experts:
Mitchell Schwaber, MD; Israel Ministry of Health, Tel Aviv, Israel.
Kevin B. Laupland, MD; Univ. of Calgary, Calgary, Canada.

 

Symposia

 

Antibiotic Combinations against Gram-Negatives in the XDR Era: From Bench to Bedside

Developed in Cooperation with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

This session will provide an overview about the role of different antibiotic combinations in the treatment of infections due to multidrug resistant gram-negative bacteria. It will specifically address in-vitro synergy-testing of antimicrobial agents, examine the role of animal modeling for combination therapy and describe if the combination of active antibiotics influences the outcome of infections due to multi-resistant gram-negative bacteria.

Upon completion of this Symposium Session, the participant should be able to:

  • Recommend when in vitro synergy-testing of antimicrobial agents is indicated for gram-negatives;
  • Examine the role of animal modeling for combination therapy for gram-negative infections; and 
  • Describe if the combination of active antibiotics influences the outcome of infections due to multi-resistant gram-negative bacteria. 

Conveners:
Jesús Rodríguez-Baño, MD, PhD; Hosp. Univ. Virgen Macarena and Univ. of Seville, Seville, Spain.
Johann D. Pitout, MD; Univ. of Calgary, Calgary, Canada.

Presentations:
Truths and Half Truths About In Vitro Synergy against Gram-Negatives
Shawn Aaron, MD; The Ottawa Hosp. Res. Inst., Univ. of Ottawa, Ottawa, Canada.

Animal Modeling for Combined Therapy for Gram-Negative Infections: A Critical Appraisal
Vincent H. Tam, PharmD; Univ. of Houston Coll. of Pharmacy, Houston, TX.

Combination Antibiotics and Outcome of Life-Threatening Bacterial Infections and Septic Shock
Anand Kumar, MD; Univ. of Manitoba, Hlth. Sci. Ctr., Winnipeg, Canada.

 

Global Spread of Antimicrobial Resistance: Mechanisms of Spread, Surveillance, and Control

This session will provide an overview on the challenges of the global spread of antimicrobial resistance. It will specifically address different mechanisms and the spread of antimicrobial resistance. This session will also provide an overview on the worldwide progress of controlling antimicrobial resistance and highlight the role of new technologies in surveillance and control of antimicrobial resistance.

Upon completion of this Symposium Session, the participant should be able to:

  • Discuss the global differences and mechanisms for spread of antimicrobial resistance;
  • Describe the progress on recognizing antimicrobial resistance on a worldwide basis; 
  • Review the role of new technologies in furthering or improving global surveillance; and
  • Evaluate the European model for antimicrobial surveillance and control. 

Conveners:
Didier Pittet, MD, MS; Univ. of Genèva Hosp., Genèva, Switzerland.
Jesús Rodríguez-Baño, MD, PhD; Hosp. Univ. Virgen Macarena and Univ. of Seville, Seville, Spain.

Presentations:
Overview of Global Differences and Mechanisms for Spread
Neil Woodford, PhD, FRCPath; Hlth. Protection Agency, London, United Kingdom.

Building Capacity for Diagnosing Resistance Worldwide: Are We Making Any Progress?
Keith P. Klugman, MD, PhD; Rollins Sch. of Publ. Hlth., Emory Univ., Atlanta, GA.

New Technologies: Towards Global Surveillance and Prediction?
Hajo Grundmann, MD, PhD; Univ. Med. Ctr. Groningen, Rijksuniversiteit Groningen, Groningen, Netherlands.

Surveillance Spread and Control: Should We All Use the European Model?
Herman Goossens, MD, PhD; Univ. Hosp. Antwerp, Antwerp, Belgium.

 

Population Dynamics in Streptococcus pneumoniae

This session will provide an update on the population dynamics in Streptococcus pneumoniae. It specifically will address recent developments on the serotypes and clonal distribution of S. pneumoniae post-PCV13 in the USA, the role of next generation sequencing in the molecular epidemiology of S. pneumoniae, explore the role of virulence factors and provide and update on platforms and methodologies for serotyping S. pneumoniae.

Upon completion of this Symposium Session, the participant should be able to:

  • Provide an update on the serotype and clonal distribution post-PCV13 in USA;
  • Recognize the role of next generation sequencing in the molecular epidemiology of S. pneumoniae;
  • Describe the importance of different virulence factors in infections due to S. pneumoniae; and 
  • Recommend the most appropriate serotyping methodologies for Streptococcus pneumoniae. 

Conveners:
Lesley McGee, PhD; CDC, Atlanta, GA.
Stephen Bentley, PhD; Wellcome Trust Sanger Inst., Hinxton, United Kingdom.

Presentations:
Status Update on Serotype and Clonal Distribution Post-PCV13 in USA
Bernard Beall, PhD; CDC, Atlanta, GA.

Defining Evolution Streptococcus pneumoniae: Use of Next Generation Sequencing
Stephen Bentley, PhD; Wellcome Trust Sanger Inst., Hinxton, United Kingdom.

Streptococcus pneumoniae: Virulence Factors and Variation
Tim J. Mitchell, PhD; Univ. of Birmingham, Glasgow, United Kingdom.

Serotyping Methodologies for Streptococcus pneumoniae
Catherine Satzke, PhD; Murdoch Childrens Res. Inst., Melbourne, Australia.

 

Whole Genome Sequencing and Molecular Epidemiology: The New Frontier?

Developed in Cooperation with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

This session will provide an overview on the future role of whole genome sequencing in the molecular epidemiology of antimicrobial resistant bacteria. It will provide an overview on the progress and challenges of next generation sequencing and specifically address the role of this technology in the characterization of MRSA, Clostridium dificilli and the Escherichia coli O104:H4 outbreak.

Upon completion of this Symposium Session, the participant should be able to:

  • Describe the progress, opportunities and challenges of high-throughput sequencing in molecular epidemiology;
  • Recognize the role of next generation sequencing in the Escherichia coli O104:H4 outbreak; 
  • Evaluate the role of next generation sequencing in the molecular epidemiology of MRSA; and
  • Evaluate the role of next generation sequencing in the molecular epidemiology of Clostridium difficile. 

Conveners:
Mark Pallen, MD; Univ. of Birmingham, Birmingham, United Kingdom.
Robert A. Bonomo, MD; Louis Stokes Cleveland Dept. of VA Med. Ctr., Cleveland, OH.

Presentations:
High-Throughput Sequencing and Molecular Epidemiology: Progress, Opportunities and Challenges
Mark Pallen, MD; Univ. of Birmingham, Birmingham, United Kingdom.

Next Generation Sequencing Technology and Gram-Negatives: Escherichia coli O104:H4
Nicholas J. Loman, BSc, MB BS; Univ. of Birmingham, Birmingham, United Kingdom.

Next Generation Sequencing Technology and Gram-Positives: Methicillin-Resistant Staphylococcus aureus
Patrice Francois, PhD; Univ. Hosp. of Geneva, Geneva, Switzerland.

Generation Sequencing Technology and Gram-Positives: Clostridium difficile
Yung-Fu Chang, DVM, PhD; Cornell Univ., Ithaca, NY.

American Society For Microbiology © 2012

Top Desktop version